WallStSmart

Ardent Health Partners, Inc. (ARDT)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 1024% more annual revenue ($72.25B vs $6.43B). LLY leads profitability with a 35.0% profit margin vs 2.1%. ARDT trades at a lower P/E of 9.7x. LLY earns a higher WallStSmart Score of 78/100 (B+).

ARDT

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: 2.04

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.06

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARDT2 strengths · Avg: 10.0/10
P/E RatioValuation
9.7x10/10

Attractively priced relative to earnings

Price/BookValuation
0.9x10/10

Reasonable price relative to book value

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$948.95B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.9%10/10

Earnings expanding 169.9% YoY

Areas to Watch

ARDT4 concerns · Avg: 2.8/10
Market CapQuality
$1.32B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
7.7%3/10

ROE of 7.7% — below average capital efficiency

Profit MarginProfitability
2.1%3/10

2.1% margin — thin

EPS GrowthGrowth
-3.4%2/10

Earnings declined 3.4%

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.393/10

Elevated debt levels

Price/BookValuation
32.4x2/10

Trading at 32.4x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ARDT

The strongest argument for ARDT centers on P/E Ratio, Price/Book.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bear Case : ARDT

The primary concerns for ARDT are Market Cap, Return on Equity, Profit Margin. Thin 2.1% margins leave little buffer for downturns.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.

Key Dynamics to Monitor

ARDT profiles as a value stock while LLY is a growth play — different risk/reward profiles.

LLY is growing revenue faster at 55.5% — sustainability is the question.

LLY generates stronger free cash flow (3.0B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (78/100 vs 49/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ardent Health Partners, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Ardent Health Partners, Inc., based in Nashville, Tennessee, is a leading healthcare organization committed to providing exceptional, patient-centered care via its robust network of hospitals and outpatient facilities. With a reputation for innovation and quality, Ardent boasts a diverse portfolio of acute care hospitals and is focused on developing healthcare solutions that address the unique needs of the communities it serves. Supported by a strong financial foundation and a strategic growth plan, the company is strategically positioned to expand healthcare access and enhance patient outcomes in an ever-evolving industry landscape.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?